Pharmaceutical giant Merck reported strong financial growth for the fourth quarter of 2024, with worldwide sales reaching $15.6 billion – a 7% increase from the same period last year. This represents a continuation of the company’s upward trend, as full-year 2024 sales came in at $64.2 billion, also a 7% boost.
Merck attributes this growth to demand for its innovative portfolio, including its cancer treatment KEYTRUDA. The company is also highlighting the successful launch of new medication WINREVAIR and strong performance from its Animal Health business. CEO Rob Davis expressed confidence in the company’s long-term growth potential, citing the dedication of its global team as a key factor.
Looking ahead to 2025, Merck anticipates full-year sales to be between $64.1 billion and $65.6 billion, indicating further growth for the company.
Source: https://www.merck.com/stories/our-q4-and-full-year-2024-financial-results